Eli Lilly's Orforglipron: Positive Market Outlook Following ATTAIN-1 Trial Results

Eli Lilly's orforglipron received positive feedback from key opinion leaders (KOLs) despite initial market disappointment. KOLs viewed the drug's efficacy as satisfactory to excellent, with a favorable safety and tolerability profile. Most KOLs indicated a willingness to prescribe orforglipron more frequently, particularly for patients preferring oral medication or with less severe weight loss needs. The drug's market positioning relative to Novo's oral semaglutide was seen as competitive.

Eli Lilly's (NYSE: LLY) oral GLP-1 receptor agonist, orforglipron, has received positive feedback from key opinion leaders (KOLs) despite initial market disappointment following the release of Phase 3 trial data. While the drug's efficacy fell short of some analysts' expectations, KOLs have praised its safety profile and tolerability, indicating a willingness to prescribe it more frequently, particularly for patients who prefer oral medication or have less severe weight loss needs.

KOLs rated the drug's efficacy as satisfactory to excellent, with a favorable safety and tolerability profile. This positive feedback is significant, as it suggests that orforglipron could find a niche in the market, especially among patients who prefer oral medications or have less severe weight loss needs. The drug's market positioning relative to Novo's oral semaglutide was seen as competitive, with KOLs indicating that orforglipron could be a viable alternative for certain patient populations.

Despite the mixed Phase 3 trial results, Eli Lilly remains optimistic about orforglipron's potential. The company plans to file for regulatory review by the end of 2025, and if approved, analysts believe the drug could capture a share of the growing oral GLP-1 market. While the drug's efficacy was not as high as Novo Nordisk's oral semaglutide, KOLs' positive feedback suggests that orforglipron could still be a valuable addition to the obesity and diabetes treatment landscape.

References:
1. [https://www.ainvest.com/news/eli-lilly-q2-2025-outperformance-orforglipron-pipeline-era-obesity-diabetes-therapies-2508/](https://www.ainvest.com/news/eli-lilly-q2-2025-outperformance-orforglipron-pipeline-era-obesity-diabetes-therapies-2508/)
2. [https://www.clinicaltrialsarena.com/news/viking-obesity-pill-phase-ii-results/](https://www.clinicaltrialsarena.com/news/viking-obesity-pill-phase-ii-results/)